Eos BioInnovation

Eos BioInnovation is a Boston-based venture fund and incubator focused on building and investing in early-stage regenerative medicine companies. It partners with leading academic institutions—especially Harvard Stem Cell Institute—to source cutting-edge technologies at the earliest stages. Its investments span small molecules, cell therapies, monoclonal antibodies, and biomaterials. The firm leverages enabling technologies such as genome sequencing, CRISPR gene editing, AI/automation, and maintains strong partnerships with Panacea Venture and major pharmaceutical players. Portfolio highlights include seed-stage investment in Autoimmunity BioSolutions for next-generation immuno-corrective antibody therapies targeting genetically defined autoimmune disease subpopulations.